EMG
CADX

Ellington Management Group’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Ellington Management Group’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-47,100
Closed -$426K – 910
2013
Q4 		$426K Buy
47,100
+28,100
+148% +$203K 0.15% 217
2013
Q3 		$120K Buy
+19,000
New +$121K 0.02% 715

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ellington Management Group's CADX Position: Q1 2014 in Review

Ellington Management Group sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 47,100 shares — an estimated $426K sold.

Ellington Management Group first reported a position in CADX in Q3 2013 and held it in 2 quarters. The position peaked at $426K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Ellington Management Group reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Ellington Management Group sold 47,100 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $426K.
  • Ellington Management Group first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 2 quarters.
  • Ellington Management Group's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $426K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Ellington Management Group's 13F filing for Q1 2014, filed 15 May 2014.